[(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3- CARBONYL)AMINO]ACETIC ACID (ROXADUSTAT) FOR THE TREATMENT OF ANEMIA IN SUBJECTS WITH MYELODYSPLASTIC SYNDROME (MDS)
The present invention relates to the use of roxadustat in the manufacture of a medicament for treating anemia in a subject having anemia associated with myelodysplastic syndrome (MDS). Methods for treating anemia in a subject having anemia associated with myelodysplastic syndrome comprising administering to the subject a therapeutically effective amount of roxadustat, thereby treating the anemia are also described.
The invention relates to treatment methods for improving cardiac function in subjects having congestive heart failure and particularly for preventing or reducing the decline in cardiac function that occurs subsequent to myocardial ischemia. The methods utilize compounds that selectively inhibit prolyl hydroxylase domain-containing protein 1 (PHD1). Some embodiments relate to combination therapies for treating heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
3.
[(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBONYL)AMINO]ACETIC ACID (ROXADUSTAT) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA (CIA)
FIBROGEN (CHINA) MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. (China)
Inventor
Lee, Tyson
Eisner, Mark
Abstract
The present application relates to methods of treating chemotherapy-induced anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level ≤100 g/L prior to treatment and the subject's blood hemoglobin level decreased at least 10 g/L after the initiation of chemotherapy, comprising administering roxadustat to the subject.
FIBROGEN (CHINA) MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. (China)
Inventor
Thompson, Michael D.
Cheng, Hengqin
Martinelli, Michael John
Witschi, Claudia
Shao, Zezhi Jesse
Yang, Libo
Guthrie, Niles Jens
Abstract
The present application relates to solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid of having a unimodal particle size distribution of D90 of about 21 µm to 29 µm; a D50 of about 12 µm to 17 µm; and a D10 of about 6 µm to 10 µm, and pharmaceutical compositions thereof. Preparation of the solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid of the particular particle size distribution, and use of same for the treatment of anemia is also described.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
C07C 275/40 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
Provided herein are isolated monoclonal antibody anti-CCR8 antibodies, antigen binding fragments thereof, mutants thereof, variants thereof and uses thereof for the treatment of diseases such as cancer. The mutant antibodies have a complementarity-determining region 3 modified to eliminate post-translational modification, and to improve stability and potency of the antibody. The variant antibodies have various levels of afucosylation. Also provided herein are methods of use of the anti-CCR8 antibodies, including methods of treatment of cancer. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vector, including the polynucleotides described herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided herein are affinity matured anti-galectin-9 (Gal9) antibodies. The antibodies have improved binding affinity to Gal9. Also provided herein are method of use of the affinity matured anti-Gal9 antibodies, including methods of treatment of cancer, methods of rescuing or promoting effector T cell proliferation, methods of enhancing effector T cell activity, and/or of identifying and treating cancer in a subject including the administration of the anti-Gal9 antibodies described herein. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vectors, including the polynucleotides described herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
11.
COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
C07D 213/65 - One oxygen atom attached in position 3 or 5
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 255/56 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, gastrointestinal diseases and disorders
The invention relates to treatment methods for improving cardiac function in subjects having congestive heart failure and particularly for preventing or reducing the decline in cardiac function that occurs subsequent to myocardial ischemia. The methods utilize compounds that selectively inhibit prolyl hydroxylase domain-containing protein 1 (PHD1). Some embodiments relate to combination therapies for treating heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines
15.
COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
C07D 215/50 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of chronic
fibrotic and proliferative disorders; pharmaceutical
preparations for the treatment of cancer, muscular dystrophy
and idiopathic pulmonary fibrosis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of chronic fibrotic and proliferative disorders; pharmaceutical preparations for the treatment of cancer, muscular dystrophy and idiopathic pulmonary fibrosis.
The invention relates to methods and agents useful for treating muscular dystrophies (MDs), in particular, Duchenne muscular dystrophy (DMD). Methods and agents for treating various physiological and pathological features associated with muscular dystrophies are also provided.
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07C 255/56 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of chronic fibrotic and proliferative disorders; pharmaceutical preparations for the treatment of cancer, muscular dystrophy and idiopathic pulmonary fibrosis
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Connective Tissue Growth Factor (CTGF) and anti-connective tissue growth factor antibodies for research and diagnostic use; prolyl hydroxylase inhibitors for research use Connective Tissue Growth Factor (CTGF) and anti-connective tissue growth factor antibodies for clinical and pharmaceutical use; prolyl hydroxylase inhibitors for clinical or pharmaceutical use
01 - Chemical and biological materials for industrial, scientific and agricultural use
02 - Paints, varnishes, lacquers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Recombinant collagens for research use; synthetic gelatin
for research use; anti-connective tissue growth factor
antibodies for research and diagnostic use; prolyl
hydroxylase inhibitors for research use; recombinant
collagen for use in manufacturing pharmaceutical products
and veterinary products. Recombinant collagen coating for use on labware and medical
devices. Anti-connective tissue growth factor antibodies for clinical
or pharmaceutical use; recombinant collagen for clinical or
pharmaceutical use; synthetic gelatin for clinical or
pharmaceutical use; recombinant collagen for use as a dermal
filler or as a pharmaceutical preparation for dermal
implantation; prolyl hydroxylase inhibitors for clinical or
pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, in particular, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, central and peripheral nervous systems diseases and disorders, infection, namely, anti-infectives and inflammation, namely, anti-inflammatories
26.
METHODS OF TREATING DIDIOPATHIC PULMONARY FIBROSIS
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.
01 - Chemical and biological materials for industrial, scientific and agricultural use
02 - Paints, varnishes, lacquers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Synthetic gelatin for research use; anti-connective tissue
growth factor antibodies for research and diagnostic use;
prolyl hydroxylase inhibitors for research use; recombinant
collagen for use in manufacturing pharmaceutical products
and veterinary products; recombinant collagens for research
use. Recombinant collagen coating for use on labware and medical
devices. Recombinant collagen for clinical or pharmaceutical use;
synthetic gelatin for clinical or pharmaceutical use;
recombinant collagen for use as a dermal filler or as a
pharmaceutical preparation for dermal implantation; prolyl
hydroxylase inhibitors for clinical or pharmaceutical use;
anti-connective tissue growth factor antibodies for clinical
or pharmaceutical use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
02 - Paints, varnishes, lacquers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Recombinant collagens for research use; synthetic gelatin for research use; anti-connective tissue growth factor antibodies for research and diagnostic use; prolyl hydroxylase inhibitors for research use; recombinant collagen for use in manufacturing pharmaceutical products and veterinary products
(2) Recombinant collagen coating for use on labware and medical devices
(3) Anti-connective tissue growth factor antibodies for clinical and pharmaceutical use; recombinant collagen for clinical and pharmaceutical use; synthetic gelatin for clinical and pharmaceutical use; recombinant collagen for use as a dermal filler and as a pharmaceutical preparation for dermal implantation; prolyl hydroxylase inhibitors for clinical and pharmaceutical use
01 - Chemical and biological materials for industrial, scientific and agricultural use
02 - Paints, varnishes, lacquers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Synthetic gelatin for research use; anti-connective tissue growth factor antibodies for research and diagnostic use; prolyl hydroxylase inhibitors for research use; recombinant collagen for use in manufacturing pharmaceutical products and veterinary products; recombinant collagens for research use
(2) Recombinant collagen coating for use on labware and medical devices
(3) Recombinant collagen for clinical and pharmaceutical use; synthetic gelatin for clinical and pharmaceutical use; recombinant collagen for use as a dermal filler and as a pharmaceutical preparation for dermal implantation; prolyl hydroxylase inhibitors for clinical and pharmaceutical use; anti-connective tissue growth factor antibodies for clinical and pharmaceutical use
30.
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.
The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for use in oncology and for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely central nervous system infections, brain diseases, depression, anxiety, central nervous system movement disorders, and spinal cord diseases; pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; pharmaceutical preparations and substances for use in pain control and local and general anesthetics; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations, namely, anti-infective
34.
Methods for treating idiopathic pulmonary fibrosis
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Recombinant collagens for research use; synthetic gelatin for research use; recombinant collagen for use in manufacturing pharmaceutical products Recombinant collagen for clinical or pharmaceutical use; synthetic gelatin for clinical or pharmaceutical use
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
anti-connective tissue growth factor antibodies for research and diagnostic use; prolyl hydroxylase inhibitors for research use Anti-connective tissue growth factor antibodies for clinical or pharmaceutical use; prolyl hydroxylase inhibitors for clinical or pharmaceutical use
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic food and
substances adapted for medical or veterinary use, food for
babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations for use in oncology; pharmaceutical
preparations for the treatment of cardiovascular diseases
and disorders, metabolic diseases and disorders, respiratory
diseases and disorders, gastrointestinal diseases and
disorders, nervous system diseases and disorders, infection
and inflammation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic food and
substances adapted for medical or veterinary use, food for
babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations for use in oncology; pharmaceutical
preparations for the treatment of cardiovascular diseases
and disorders, metabolic diseases and disorders, respiratory
diseases and disorders, gastrointestinal diseases and
disorders, nervous system diseases and disorders, infection
and inflammation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic food and
substances adapted for medical or veterinary use, food for
babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides; pharmaceutical
preparations for use in oncology; pharmaceutical
preparations for the treatment of cardiovascular diseases
and disorders, metabolic diseases and disorders, respiratory
diseases and disorders, gastrointestinal diseases and
disorders, nervous system diseases and disorders, infection
and inflammation.
46.
Methods for treating idiopathic pulmonary fibrosis
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation.
50.
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof.
The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
59.
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
63.
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
65.
PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR
The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7- phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
C07D 498/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
68.
CRYSTALLINE FORMS OF {[1-CYANO-5-(4-CHLOROPHENOXY)-4-HYDROXY-ISOQUINOLINE-3-CARBONYL]-AMINO}-ACETIC ACID
The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof.
The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 39/00 - Medicinal preparations containing antigens or antibodies
71.
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
72.
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
The present mvention relates to methods and medicainsnts useful for treating idiopathic pulmonary fibrosis (IFF) by administermg anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. In one aspect, the present invention provides a method of treating a subject with peritoneal carcinomatosis, the method comprises the administration to the subject of an effective amount ohm anti-connective tissue growth factor (CTGF) agent, thereby treating the peritoneal carcinomatosis. In some embodiments, the peritoneal carcinomatosis results from a cancer selected from the group consisting of gall bladder cancer, bile duct cancer, liver cancer, colon cancer, cancer of the appendix, ovarian cancer, fallopian tube cancer, bladder cancer, pancreatic cancer, mesothelioma, rectal cancer, small bowel cancer and stomach cancer. In particular embodiments, the cancer is ovarian cancer. In further embodiments, the ovarian cancer is classified as serous, clear cell, mucinous or endometrioid.
The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (LDL-C) and/or very low density Opoproiein cholesterol (VLDL-C) in subjects In need thereof by administering a compound that inhibits HIF hydroxylase activity. The method is useful, for reducing LDL cholesterol levels and total cholesterol levels even In subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia.
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present invention provides a method of treatment for anemia, or of increasing the hemoglobin level, in a subject without significantly increasing the platelet count during the course of treatment, by administering a compound that inliibits HIF prolyl hydroxylase.
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Described herein are methods for treating connective tissue growth factor (CTGF) -associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
83.
METHODS FOR INCREASING RETICULOCYTE HEMOGLOBIN CONTENT
The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing reticulocyte hemoglobin content are provided.
The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing mean corpuscular volume are provided. Methods and compounds for treating microcytosis and methods and compounds for treating microcytic anemia are also provided.
The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.
The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.
The present disclosure relates to methods and medicaments useful for pre - treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
The present invention relates to methods and medicaments useful for treatment of radiation-induced disorders by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments for pre-treating individuals having or at risk for having exposure to ionizing radiation to prevent or reduce radiation-induced disorders are also provided.
The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
93.
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
94.
Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
C07D 311/02 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
95.
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
C07D 221/02 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups condensed with carbocyclic rings or ring systems
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61P 25/00 - Drugs for disorders of the nervous system
C07C 63/00 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings
C07C 65/00 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups
C12N 9/99 - Enzyme inactivation by chemical treatment
The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
97.
METHODS FOR TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS
The present invention relates to methods and agents for treating, preventing, or reversing podocyte injury or podocyte-associated disorders. Methods and agents for treating or preventing podocytopathies (i.e. podocytopathy (i.e. podocyte disease)s) are also provided.
The present invention relates to methods and compounds useful for increasing neurogenesis. Methods and compounds for increasing dopaminergic differentiation are also provided. Methods for treating neurological disorders by increasing neurogenesis are also provided.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/4743 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
